Immunocore Hldgs Analyst Ratings
Immunocore Hldgs Analyst Ratings
Buy Rating Affirmed: Immunocore's Promising Survival Data and High Disease Control Rate in Advanced Melanoma
Buy Rating on Immunocore Holdings Backed by Promising Phase I/II Study Results and Potential T-cell Profile Benefits
Positive Outlook for Immunocore's KIMMTRAK Bolsters Buy Rating Amidst Advancing Clinical Trials
Needham: Reiterated the Immunocore Hldgs (IMCR.US) rating, adjusted from buy to buy rating, and adjusted the target price from $81.00 to $81.00.
Immunocore Hldgs Analyst Ratings
Immunocore Hldgs Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)
Needham: Reiterates Immunocore Hldgs (IMCR.US) rating and adjusted from buy to buy rating, target price is $81.00.
Immunocore Hldgs Analyst Ratings
Immunocore Holdings (IMCR) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Cresco Labs (OtherCRLBF) and Immunocore Holdings (IMCR)
Optimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic Developments
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Immunocore Hldgs Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
No Data